New inhaled drug shows promise for easing lung pressure in rare Heart-Lung condition
NCT ID NCT05343637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an inhaled medication called RT234 in 14 adults with pulmonary arterial hypertension (PAH), a condition where blood pressure in the lungs is dangerously high. The goal was to see if the drug could quickly lower lung blood pressure during a heart catheterization procedure. The study also checked for side effects like headache or cough. This is an early-phase trial to gather safety and effectiveness data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
-
St Vincent's Hospital
Darlinghurst, New South Wales, 2010, Australia
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests